Prospective Randomized Trial of Postoperative Adjuvant Therapy in Patients with Completely Resected Stage II and Stage IIIa Non-Small Cell Lung Cancer, Intergroup

EGFr dinucleotide repeat polymorphism in non-small cell lung cancer

S Dubey;J Miller;P Stephenson;SM Keller;DH Johnson;JH Schiller;JM Kolesar Proc of the American Society of Clincial Oncology 23:852 (#9585)

Post-operative radiotherapy (PORT) or chemoradiotherapy (CPORT) following resection of stages II and IIIa non-small cell lung cancer (NSCLC) leads to higher than expected risk of death from intercurrent disease (DID).

HA Wakelee;P Stephenson;SM Keller;H Wagner;A Herskovic;R Komaki;RS Marks;MC Perry;RB Livingston;DH Johnson Proc of the American Society of Clinical Oncology 22:633(#2545)

The influence of gender on survival and tumor recurrence following adjuvant therapy of cmopletely resected stages II and IIIa non-small cell lung cancer.

SM Keller;MG Vangel;S Adak;H Wagner;JH Schiller;A Herskovic;R Komaki;MC Perry;RS Marks;RB Livingston;DH Johnson Lung Cancer 37:303-309

A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIA non-small-cell lung cancer

SM Keller;S Adak;H Wagner;A Herskovic;R Komaki;BJ Brooks;MC Perry;RB Livingston;DH Johnson New England Journal of Medicine 343(17):1217-1222

Prospective randomized trial of postoperative adjuvant therapy in patients with completely resected stages II and IIIa non-small cell lung cancer: an Intergroup trial (E3590).

SM Keller;S Adak;H Wagner;A Herskovic;BJ Brooks;MC Perry;RB Livingston;DH Johnson Proc of the American Society of Clinical Oncology 18:465a(#1793)

Cisplatin (P) & etoposide (E) + concurrent thoracic radiotherapy (TRT) administered once versus twice daily for limited-stage (LS) small cell lung cancer (SCLC): Preliminary results of an intergroup trial.

DH Johnson;K Kim;AT Turrisi;W Sause;R Komaki;H Wagner;R Blum ASCO 13:333(#1105)